<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149710">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01956188</url>
  </required_header>
  <id_info>
    <org_study_id>Omega 3 and Lupus USP</org_study_id>
    <nct_id>NCT01956188</nct_id>
  </id_info>
  <brief_title>Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been demonstrated that EPA and DHA supplementation may have anti-inflammatory
      properties in several chronic diseases, namely, diabetes, obesity, and in rheumatoid
      arthritis, although not with controversy. Systemic lupus erythematosus is an autoimmune
      disease characterized by a chronic inflammatory state which is associated with the disease´s
      clinical symptoms. Thus, we hypothesized that EPA and DHA supplementation may beneficially
      affect the inflammatory cytokine profile and clinical features of LES patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Cytokine profile (serum levels of IL-1B, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-alpha, IFN-y)</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cytokines´ serum levels (pg/ml) will be assessed by Elisa kits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clical features</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Disease activity - assessed by SLEDAI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical features</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life - assessed by SF-36 questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical features</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fatigue - assessed by 2 questionaires - Chalders´Fatigue Scale and Fatigue Severity Scale (FSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical features</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Body composition - lean (Kg) and fat mass (Kg) assessed by air displacement pletysmography (BOD POD).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>EPA and DHA supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EPA (1800mg/d) and DHA (1200mg/d) supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Soy oil (3000 mg/d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>EPA and DHA supplementation</intervention_name>
    <description>Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.</description>
    <arm_group_label>EPA and DHA supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will be given 3g/d of soy oil - 5 capsules per day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 7 and 40 years

          -  SLEDAI ≤ 4

        Exclusion Criteria:

          -  Cardiovascular dysfunction

          -  Rhythm and conduction disorders

          -  Musculoskeletal disturbances

          -  Kidney and pulmonary involvements

          -  Peripheral neuropathy

          -  Use of tobacco

          -  Treatment with lipid-lowering or hypoglycemic drugs

          -  Fibromyalgia

          -  Use of chronotropic or antihypertensive drugs

          -  Physically active subjects
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabiana Benatti, PhD</last_name>
    <phone>55-11-3091-8783</phone>
    <email>benatti@usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>General Hospital - University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05.403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro</last_name>
      <phone>55-11-2661-8022</phone>
    </contact>
    <investigator>
      <last_name>Marina Solis</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 1, 2013</lastchanged_date>
  <firstreceived_date>September 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Fabiana Braga Benatti</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
